Related Experiment Video
Updated: May 25, 2026
06:55
An Integrated Method for Crafting Flexible and Convenient Electrophysiological Optrodes for Multi-Region In Vivo Recording
Published on: November 21, 2024
Emerging technology for advancing the treatment of epilepsy using a dynamic control framework
Scott Stanslaski1, John Giftakis, Paul Stypulkowski
1Neuroengineering Group of Medtronic Neuromodulation Technology. timothy.denison@medtronic.com
Summary
This study presents a dynamic control system for neuromodulation therapy in epilepsy, validating key technologies in an animal model to improve treatment effectiveness and patient outcomes.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Control Systems
Background:
- Neuromodulation for epilepsy treatment can be conceptualized within a dynamic control framework.
- Current limitations in neuromodulation stem from challenges in system observability and controllability.
- Improving sensor and actuator performance, alongside disease state dynamics understanding, is crucial for better therapeutic outcomes.
Purpose of the Study:
- To describe a dynamic control system framework for neuromodulation in epilepsy.
- To address practical challenges and validate prototype technologies for epilepsy neuromodulation.
- To enhance the observability and controllability of neuromodulation systems.
Main Methods:
- Development of a dynamic control system framework for neuromodulation.
- Utilizing a chronic animal model for epilepsy research.
- Preliminary validation of key 'observability' and 'controllability' technology prototypes.
Main Results:
- Demonstrated preliminary validation of critical 'observability' and 'controllability' technology blocks.
- Successful testing of emerging technologies within a representative neural network in an epilepsy model.
- Established a foundation for understanding neural network behavior and optimizing therapy design.
Conclusions:
- The described framework and validated technologies offer a potential pathway for optimizing epilepsy neuromodulation.
- Future advancements may lead to a deeper understanding of neural network dynamics.
- These developments pave the way for practical clinical translation of advanced neuromodulation therapies.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...